CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease

The development of cyclin-dependent kinase (CDK) 4/6 inhibitors has been more prominent in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, with a significant improvement in progression-free survival (PFS) in first and later lines of metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Matutino, Adriana, Amaro, Carla, Verma, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299331/
https://www.ncbi.nlm.nih.gov/pubmed/30619511
http://dx.doi.org/10.1177/1758835918818346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299331/
https://www.ncbi.nlm.nih.gov/pubmed/30619511
http://dx.doi.org/10.1177/1758835918818346

Ejemplares similares